Research On Anti - Tumor Product Marketing Strategy Of H Company

In twenty-first Century, China’s economy has been rapid development, comprehensive strength continuously improve, but environmental pollution and ecological damage is becoming more and more serious. The ecological destruction caused by contamination of food and water supplies, the fast pace of life makes people the pressure increases, the incidence of many diseases are increasing. According to the world cancer report 2012, malignant tumors of all over the world every year new patients about 14 million, deaths" of about 8million, in new patients, the Chinese residents accounted for 22% of the world total incidence and deaths accounted for 26%, more than a quarter of the total number of deaths in patients with cancer around the world.In 2014 the total output value of China’s pharmaceutical industry reached 2579.8 billion yuan, an increase of 15.7%. Is expected in 2020 Chinese will become the second largest pharmaceutical production and consumption country. From a global perspective, the pharmaceutical industry in a weak global economy thriving. According to IMS statistics, the scale of the global pharmaceutical market in 2014 (excluding medical instruments) about ＄1065 billion, the medical device market is about ＄345 billion.Premier Li Keqiang in the new medical reform emphasizes three doctors linkage, namely "health care, health care, medicine" closely integrated, collaborative reform. In under the guidance of scientific government also appeared some new phenomenon, Sanming mode, Ningbo mode, Wuhai mode are pioneer of reform, has also become a hot topic in the medical industry in 2015. In the national health insurance, saving control-the cost of the background, China’s pharmaceutical enterprises to keep up with the pulse of the times, in R & D and innovation ability, operation ability and marketing ability obtain comprehensive ascension to become the pharmaceutical enterprises are facing an important issue.Aptinib Mesylate Tablet is a new target to anticancer drugs, which belongs to the independent research and development of 1.1 class of drugs, the products in this field has stood in the pharmaceutical enterprises in the first echelon of the starting line. But the accumulation and accumulation of R & D experience, and can not be fully used in the operation of the market for the product. A excellent, innovative products, not only to the effect of treatment on have obvious advantages, but also in the operation of the market and marketing planning have outstanding performance, is the only way to stand out in many of his competitors, economic benefits and social benefits of the double harvest. Aptinib Mesylate Tablet for Nepal’s marketing model successfully and no, but also related to the behind other products future economic value and market prospect. Therefore, the use of the basic theory and analysis method of marketing, in-depth research and analysis of Aptinib Mesylate Tablet marketing programs and from the accumulation of experience on subsequent product market operation also has important significance.